Wave Life Sciences disclosed Phase 1 data from its first-in-human Inlight trial of WVE-007, an INHBE GalNAc-siRNA candidate for obesity, and the market reacted sharply. Investors pulled back after the study’s six-month body weight outcome showed only a small average reduction, despite the company highlighting body composition changes. The trial tested a 250 mg dose in otherwise healthy overweight or obese adults. While Wave described improvements in body composition measures such as fat loss with muscle preservation, the modest weight effect was a focal point for analysts and traders. The update increases pressure on Wave to demonstrate clearer clinical translation from early biomarkers to endpoints that investors and future pivotal designs can underwrite.